Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022

Rhea-AI Summary

Aethlon Medical (Nasdaq: AEMD) will announce its second-quarter financial results for the period ending September 30, 2022, on November 14, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss the results and corporate developments. The Hemopurifier, a breakthrough device, is being evaluated for treating cancer and infectious diseases. Notably, it has shown potential in removing harmful exosomes related to cancer and treating COVID-19 patients, demonstrating effectiveness in binding and removing the SARS-CoV-2 virus.

Positive

• Hemopurifier designated as a Breakthrough Device by the FDA.
• Successful demonstration of Hemopurifier binding to SARS-CoV-2 spike protein.

Negative

• No significant revenue or earnings data disclosed in the PR.

SAN DIEGO, Nov. 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter ended September 30, 2022, at 4:15 p.m. EST on Monday, November 14, 2022.

Management will host a conference call on Monday, November 14, 2022 at 4:30 p.m. EST to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10172901/f4fe08e0d7. Please note that registered participants will receive their dial in number upon registration.

Interested parties without internet access or unable to pre-register may dial in by calling: 
PARTICIPANT DIAL IN (TOLL FREE):           1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN:     1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call. 

A replay of the call will be available approximately one hour after the end of the call through December 14, 2022. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 2753791.

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.

The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Study (EFS) to evaluate the Hemopurifier for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies. A recent amendment to the IDE enabled Aethlon to implement a new EFS protocol to treat up to 40 COVID-19 patients at up to 20 clinical sites in the U.S.  In two case studies of patients treated under Emergency Use (EU), the Hemopurifier demonstrated binding of SARS-CoV-2 spike protein and removal of SARS-CoV-2 virus from the circulation of a human patient.

Additional information can be found at www.AethlonMedical.com.

Company Contact:

Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc. 
Jfrakes@aethlonmedical.com

Investor Contact:

Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com 
212-966-3650

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-november-14-2022-301666682.html

SOURCE Aethlon Medical, Inc.

FAQ

When will Aethlon Medical release its second quarter financial results?

Aethlon Medical will release its financial results on November 14, 2022, at 4:15 p.m. EST.

What is the purpose of the Hemopurifier by Aethlon Medical?

The Hemopurifier is designed to treat cancer and life-threatening infectious diseases by filtering harmful exosomes and viruses from the blood.

What is the significance of the FDA Breakthrough Device designation for the Hemopurifier?

The FDA Breakthrough Device designation allows for expedited development and review for devices that show promise in treating serious conditions.

What should investors expect from Aethlon Medical's upcoming conference call?

Investors can expect a review of financial results and corporate developments during the conference call on November 14, 2022.